Drug intelligence / Profile preview

SVT-DME01

Development stage: Preclinical
Lead developer: Laboratorios Salvat
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Ophthalmic, Topical

Overview

SVT-DME01 is a topical corticosteroid nanoemulsion in development by Laboratorios Salvat for the treatment of Diabetic Macular Edema (DME). It utilizes the proprietary IMPACT-SVT® technology platform to enhance the delivery of the active corticosteroid to the retinal tissue via topical ophthalmic administration. This approach is intended to provide a non-invasive alternative to the intravitreal injections currently used as the standard of care for DME. The drug works by reducing retinal inflammation and vascular permeability, which are key drivers of macular edema in diabetic patients. It is formulated in single-dose, preservative-free containers.

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on SVT-DME01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SVT-DME01.

Explore the full profile